Trials / No Longer Available
No Longer AvailableNCT04705454
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- ADC Therapeutics S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC Therapeutics will evaluate patients for approval into the program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Loncastuximab Tesirine |
Timeline
- First posted
- 2021-01-12
- Last updated
- 2021-05-12
Source: ClinicalTrials.gov record NCT04705454. Inclusion in this directory is not an endorsement.